BACKGROUND: Intradermally administered influenza vaccine is as immunogenic as intramuscular vaccine at a lower unit dose. New microinjection systems could allow self-administration of vaccine, potentially reducing the cost and inconvenience. OBJECTIVE: To compare the immunogenicity, reactogenicity, success rate, and acceptability of self- versus nurse-administered intradermal trivalent seasonal influenza vaccine. METHODS:Adults (18-59 years old) were randomized to either self- or nurse-administered intradermal vaccine. Prior to vaccination, participants completed a questionnaire and had blood drawn for hemagglutination inhibition titres. Participants in the nurse-administered group were vaccinated by study personnel. The self-administered group were given an instruction sheet and administered their own vaccine. All participants completed a questionnaire and adverse event diaries for 21 days post vaccination, at which time blood was again collected. RESULTS: Of the 228 participants, 115 were randomized to self-administration and 113 to nurse administration. Groups did not differ by sex, age, or levels of seroprotection at baseline. Of the 114 who completed self-administration, 106 (93%) were successful on the first attempt. There were no group differences in measures of immunogenicity for any of the strains. Self-administering participants reported a lower mean pain rating at vaccination but had larger areas of redness post-vaccination. Seventy percent of all participants said they would prefer intradermal over intramuscular vaccinations in the future, if given the choice. CONCLUSION: Compared to nurse-administered intradermal influenza vaccine, self-administered vaccine was immunologically non-inferior and reached all EMA immunogenicity criteria for the A strains, was highly successful and well-accepted by study participants. Together, these data provide preliminary evidence of feasibility for this method of influenza vaccine administration, which may improve vaccine uptake in adults and increase efficiency of vaccine delivery during outbreaks.
RCT Entities:
BACKGROUND: Intradermally administered influenza vaccine is as immunogenic as intramuscular vaccine at a lower unit dose. New microinjection systems could allow self-administration of vaccine, potentially reducing the cost and inconvenience. OBJECTIVE: To compare the immunogenicity, reactogenicity, success rate, and acceptability of self- versus nurse-administered intradermal trivalent seasonal influenza vaccine. METHODS: Adults (18-59 years old) were randomized to either self- or nurse-administered intradermal vaccine. Prior to vaccination, participants completed a questionnaire and had blood drawn for hemagglutination inhibition titres. Participants in the nurse-administered group were vaccinated by study personnel. The self-administered group were given an instruction sheet and administered their own vaccine. All participants completed a questionnaire and adverse event diaries for 21 days post vaccination, at which time blood was again collected. RESULTS: Of the 228 participants, 115 were randomized to self-administration and 113 to nurse administration. Groups did not differ by sex, age, or levels of seroprotection at baseline. Of the 114 who completed self-administration, 106 (93%) were successful on the first attempt. There were no group differences in measures of immunogenicity for any of the strains. Self-administering participants reported a lower mean pain rating at vaccination but had larger areas of redness post-vaccination. Seventy percent of all participants said they would prefer intradermal over intramuscular vaccinations in the future, if given the choice. CONCLUSION: Compared to nurse-administered intradermal influenza vaccine, self-administered vaccine was immunologically non-inferior and reached all EMA immunogenicity criteria for the A strains, was highly successful and well-accepted by study participants. Together, these data provide preliminary evidence of feasibility for this method of influenza vaccine administration, which may improve vaccine uptake in adults and increase efficiency of vaccine delivery during outbreaks.
Authors: Milton Maciel; David Bauer; Robin L Baudier; Jacob Bitoun; John D Clements; Steven T Poole; Mark A Smith; Robert W Kaminski; Stephen J Savarino; Elizabeth B Norton Journal: Infect Immun Date: 2019-10-18 Impact factor: 3.441
Authors: Timothi J S Van Mulder; Stijn Verwulgen; Koen C L Beyers; Linda Scheelen; Monique M Elseviers; Pierre Van Damme; Vanessa Vankerckhoven Journal: Hum Vaccin Immunother Date: 2014 Impact factor: 3.452
Authors: Nadine G Rouphael; Michele Paine; Regina Mosley; Sebastien Henry; Devin V McAllister; Haripriya Kalluri; Winston Pewin; Paula M Frew; Tianwei Yu; Natalie J Thornburg; Sarah Kabbani; Lilin Lai; Elena V Vassilieva; Ioanna Skountzou; Richard W Compans; Mark J Mulligan; Mark R Prausnitz Journal: Lancet Date: 2017-06-27 Impact factor: 79.321
Authors: Timothy H Burgess; Clinton K Murray; Mary F Bavaro; Michael L Landrum; Thomas A O'Bryan; Jessica G Rosas; Stephanie M Cammarata; Nicholas J Martin; Daniel Ewing; Kanakatte Raviprakash; Deepika Mor; Elizabeth R Zell; Kenneth J Wilkins; Eugene V Millar Journal: Vaccine Date: 2015-06-25 Impact factor: 3.641
Authors: James J Norman; Jaya M Arya; Maxine A McClain; Paula M Frew; Martin I Meltzer; Mark R Prausnitz Journal: Vaccine Date: 2014-02-11 Impact factor: 3.641
Authors: Shannon J Heine; Jovita Diaz-McNair; Abhay U Andar; Cinthia B Drachenberg; Lillian van de Verg; Richard Walker; Wendy L Picking; Marcela F Pasetti Journal: J Immunol Date: 2014-01-22 Impact factor: 5.422